Polio never fully went away. Wild poliovirus type 1 still circulates in Afghanistan and Pakistan, the only two countries where it remains endemic, and a separate problem, vaccine-derived poliovirus, has triggered outbreaks across dozens of countries in recent years. The disease that once paralyzed hundreds of thousands of children annually has been beaten back by more than 99 percent, but that final fraction has proved stubbornly resistant to elimination. Understanding why requires looking at several interlocking problems: a vaccine that can, in rare circumstances, cause the very disease it prevents; immunity gaps left by a global policy decision in 2016; armed conflicts that block vaccinators from reaching children; and a surveillance system still learning how to detect a virus that usually causes no symptoms at all.
Where Wild Poliovirus Still Circulates
Of the three types of wild poliovirus, types 2 and 3 have been declared eradicated. Type 1 persists in just two countries. Afghanistan and Pakistan share a long, porous border, and the virus moves freely between them, particularly through populations displaced by decades of conflict and instability. Surveillance data through September 2024 confirmed ongoing wild poliovirus type 1 transmission in both countries, with cases concentrated in areas where vaccination teams struggle to gain access.1Morbidity and Mortality Weekly Report. Progress Toward Poliomyelitis Eradication — Afghanistan, January 2023–September 2024
The geography matters. Conflict-affected areas, particularly in southern Afghanistan and parts of Pakistan’s Khyber Pakhtunkhwa province, have been the hardest to vaccinate. Displaced families living in hard-to-reach zones often lack access to routine health care entirely, and armed conflict has historically caused polio to re-emerge even in countries that had previously eliminated it.2PubMed Central. The recent outbreaks and reemergence of poliovirus in war and conflict-affected areas Vaccinators in these regions face threats, bans by local authorities, and the logistical nightmare of reaching mobile populations. The virus exploits every gap in coverage.
The Vaccine-Derived Problem
The oral polio vaccine, developed by Albert Sabin in the 1950s, has been the workhorse of global eradication. It is cheap, easy to administer (just drops in the mouth), and produces strong gut immunity that helps stop transmission. But the live, weakened virus in the oral vaccine has a dangerous quirk: when it replicates inside a vaccinated child and passes into the environment through stool, it can mutate. If it circulates long enough in under-vaccinated communities, it can regain the ability to cause paralysis. This is vaccine-derived poliovirus, and it has become the dominant cause of polio cases worldwide.
The reversion happens through specific genetic changes. Research identified key positions in the virus genome, particularly in a region that does not code for proteins, where the weakened vaccine strain tends to mutate back toward the wild-type sequence. These mutations correlate with increased ability to attack nerve tissue.3PubMed. Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction For the type 3 vaccine strain, the reversion to virulence can involve as few as seven sequence differences from the parent vaccine, with a single back-mutation at one position playing a central role.4PubMed Central. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine
During January 2023 through June 2024, outbreaks of circulating vaccine-derived poliovirus were detected in 39 countries, producing 672 confirmed cases of acute flaccid paralysis across 27 of those countries.5Morbidity and Mortality Weekly Report. Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2023–June 2024 That count was down from 881 cases in 2022, but the number of affected countries stayed roughly the same. Earlier, in 2020, over a thousand vaccine-derived cases were reported globally.6PubMed Central. Vaccine Derived Poliovirus (VDPV) The scope of the problem undercuts the comforting idea that polio is a thing of the past.
How a Policy Decision Opened an Immunity Gap
In 2016, the global polio program made a calculated gamble. Since wild poliovirus type 2 had been declared eradicated in 2015, the trivalent oral vaccine (which protected against all three types) was replaced with a bivalent version covering only types 1 and 3. The reasoning was sound on paper: by removing the type 2 component, you eliminate the source of type 2 vaccine-derived virus. But the switch also meant that children born after 2016 in countries relying on oral vaccine had no type 2 gut immunity from their routine doses.
The result was a growing pool of children susceptible to type 2 poliovirus, exactly the fuel that circulating vaccine-derived type 2 strains needed to spread.7PubMed Central. Co-Administration of Novel Oral Polio Vaccine Type 2 and Bivalent Oral Polio Vaccine: Current Evidence, Challenges, and Implications for the Polio Eradication Endgame Modeling work confirmed that the withdrawal of the trivalent vaccine, combined with declining supplemental immunization campaigns, left immunity gaps for all three poliovirus types in vulnerable regions.8PubMed Central. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine Type 2 vaccine-derived outbreaks surged across sub-Saharan Africa, parts of Asia, and the Middle East, driven by exactly the dynamic the switch was meant to prevent.
A New Vaccine Designed Not to Revert
Recognizing that the old oral vaccine was both the best tool for stopping transmission and a source of new outbreaks, researchers engineered a next-generation oral polio vaccine for type 2, known as nOPV2. The idea was to lock in the genetic weakening so the virus cannot easily mutate back to a dangerous form. Early clinical data are encouraging. In trials comparing virus shed by infants who received the novel vaccine versus the traditional Sabin type 2 vaccine, the novel vaccine showed no evidence of the mutations associated with increased virulence. Shed virus from the Sabin vaccine, by contrast, had already reverted enough to cause paralysis in test animals at high rates. The novel vaccine’s shed virus was far less dangerous, with the odds of causing paralysis in mice roughly 140 times lower than for the traditional vaccine.9PubMed Central. Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials
The novel vaccine has been deployed in outbreak responses since 2021 under WHO emergency use listing, with hundreds of millions of doses administered. Whether it can close the immunity gap fast enough to prevent further type 2 outbreaks depends largely on how quickly and widely it reaches under-vaccinated children, which brings the problem back to the same access and logistical barriers that have slowed eradication for years.
Why Inactivated Vaccine Alone Is Not Enough
High-income countries, including the United States and most of Europe, switched to inactivated polio vaccine (given by injection) decades ago, precisely because it cannot cause vaccine-derived disease. It uses killed virus and is extremely effective at preventing paralysis. But it has a limitation that matters for eradication: it does not produce the strong intestinal immunity needed to stop person-to-person transmission. In a head-to-head comparison, far more people vaccinated with the inactivated vaccine shed poliovirus in their stool after being exposed, compared to those vaccinated with the oral vaccine.10PubMed. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines
This means someone vaccinated only with inactivated vaccine can still get infected with poliovirus and pass it on to others, even though they personally are protected from paralysis. The New York State outbreak in 2022 illustrated this: the virus circulated widely through a community, and the inactivated vaccine used throughout the U.S. did not produce the kind of sterilizing immunity that would stop the chain of transmission entirely.11Science of The Total Environment. Lessons learned from upstream wastewater sampling in response to poliovirus in New York State That said, inactivated vaccine can powerfully boost gut immunity in people who previously received oral vaccine, making it a valuable complement rather than a standalone solution.12PubMed Central. Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame
Silent Spread and Wastewater Surveillance
One of the trickiest things about poliovirus is that the vast majority of infections are invisible. Wild poliovirus causes paralysis in roughly one out of every 200 infections in unvaccinated people. Vaccine-derived poliovirus is even less likely to paralyze, doing so in about one in 2,000 infections.11Science of The Total Environment. Lessons learned from upstream wastewater sampling in response to poliovirus in New York State Everyone else gets a mild gut infection, or no symptoms at all, and never sees a doctor. Waiting for a paralysis case to appear before responding means the virus has already been spreading for weeks or months.
This is where wastewater surveillance has become a game-changer. Testing sewage for poliovirus can pick up silent circulation long before a paralyzed child shows up in a hospital. In New York State, upstream sampling of wastewater in specific neighborhoods showed that the 2022 outbreak was not limited to a single individual or community but was geographically widespread across Rockland County. Without that surveillance, public health officials would not have known where the virus was circulating or where to focus vaccination efforts.11Science of The Total Environment. Lessons learned from upstream wastewater sampling in response to poliovirus in New York State
Modeling of the New York wastewater data estimated that the surveillance system could detect a single polio infection among roughly 472 people connected to the sewer system, though the practical sensitivity varied enormously by treatment plant size. After three consecutive non-detections, confidence that poliovirus had been eliminated from a community ranged from less than 1 percent at large plants to 99 percent at small ones.13PubMed Central. Non-detection of emerging and re-emerging pathogens in wastewater surveillance to confirm absence of transmission risk: A case study of polio in New York The traditional gold standard for polio detection remains surveillance of acute flaccid paralysis, which tracks cases of sudden limb weakness in children.14PubMed Central. A review on health system-based surveillance for acute flaccid paralysis: technological advancements, challenges, and outlooks But relying on paralysis cases alone means you only ever see the tip of the iceberg, and the challenge of translating wastewater findings into timely public health action is still being worked out.15The Lancet. Is Polio Back? Current Outbreaks and Why It Won’t Go Away
Vaccine Hesitancy and Misinformation
Even where vaccinators can physically reach children, getting parents to accept the drops is not guaranteed. In parts of Afghanistan, qualitative research has identified a tangle of barriers: stereotypical beliefs about vaccines, cultural norms restricting women from opening the door to male vaccination teams, distrust of the government, and specific fears about vaccine safety.16PubMed Central. Breaking barriers: a qualitative study on polio vaccine hesitancy in Herat Province, Afghanistan Similar patterns play out in parts of Pakistan and Nigeria, where rumors that vaccines are a Western plot to sterilize children have circulated for years.
Social media has amplified the problem. Research has found that misinformation, disinformation, and religious fatalism spread online can meaningfully reduce polio vaccine acceptance.17PubMed Central. Ingraining Polio Vaccine Acceptance through Public Service Advertisements in the Digital Era: The Moderating Role of Misinformation, Disinformation, Fake News, and Religious Fatalism The combination of pockets of low vaccination coverage, circulating poliovirus, and high levels of international travel creates a constant risk that the virus will hop to new communities.18PubMed Central. Is polio making a comeback? The cost of vaccine hesitancy and the disparity in vaccine coverage. That is exactly what happened when poliovirus was detected in wastewater in London, New York, and Jerusalem in 2022, communities where under-vaccinated subgroups provided enough susceptible individuals for imported virus to gain a foothold.
Chronic Carriers and Lab Leaks
Two lesser-known risks keep the possibility of reintroduction alive even after transmission is stopped. The first involves people with certain immune deficiencies. If someone who cannot mount a full immune response receives the oral polio vaccine, they may be unable to clear the virus from their body. The weakened vaccine strain can replicate inside them for months or years, accumulating the mutations that restore virulence. These individuals become long-term excretors of increasingly dangerous virus, and if they shed it into communities with low immunity, it can spark outbreaks.19PubMed Central. Immunodeficiency-Related Vaccine-Derived Poliovirus (iVDPV) Infections: A Review of Epidemiology and Progress in Detection and Management Identifying these chronic carriers is difficult, particularly in low-income countries where immune deficiencies often go undiagnosed.
The second risk is laboratory containment. Research labs and vaccine manufacturers around the world hold stocks of live poliovirus, and accidental releases are not hypothetical. Since 2000, at least 21 incidents of poliovirus release from laboratories and vaccine production facilities have been documented globally, resulting in 16 poliovirus infections.20PubMed Central. Establishment of a Poliovirus Containment Program and Containment Certification Process for Poliovirus-Essential Facilities, United States 2017–2022 The WHO has developed a Global Action Plan for poliovirus containment, and countries like Nigeria have worked to identify and destroy unnecessary poliovirus materials in their laboratories.21PubMed Central. Towards an effective poliovirus laboratory containment strategy in Nigeria But as long as poliovirus exists anywhere — in freezers, in vaccine production lines, or in chronic carriers — the risk of reintroduction is real.
The Economics of Finishing the Job
Eradicating polio has cost far more and taken far longer than originally planned. The Global Polio Eradication Initiative, launched in 1988 when wild polio still paralyzed an estimated 350,000 children per year, has consumed tens of billions of dollars. An early economic analysis estimated the initiative’s net benefits at roughly 40 to 50 billion dollars through 2035, with low-income countries capturing about 85 percent of those savings through avoided disability, treatment costs, and lost productivity.22PubMed. Economic analysis of the global polio eradication initiative
Updated modeling, however, has told a less rosy story. Delays in achieving eradication combined with the widespread introduction of the more expensive inactivated vaccine significantly increased costs, bringing estimated net benefits down to about $28 billion.23PubMed Central. An Updated Economic Analysis of the Global Polio Eradication Initiative The eradication effort still pencils out as cost-effective, but the margin keeps shrinking as the timeline extends. What strengthens the case for pushing through to the finish is the cost of the alternative: modeling of permanent control (vaccinating indefinitely without ever stopping) shows annual costs staying above $1 billion through the 2040s, with cumulative spending overtaking the eradication path as early as 2032.24The Journal of Infectious Diseases. Projection of Costs of Polio Eradication Compared to Permanent Control In other words, giving up on eradication does not save money. It just means paying forever.
A Condition That Resembles Polio but Is Not
Since 2014, periodic spikes of a polio-like paralysis condition in children have drawn media attention and confusion. This condition, called acute flaccid myelitis, attacks the spinal cord in a pattern similar to polio and can cause lasting limb weakness. It has been linked to enterovirus D68, a different virus in the same family as poliovirus. Surges of enterovirus D68 infections in 2014 and 2016 coincided geographically and temporally with increases in acute flaccid myelitis cases, and the virus was found in respiratory samples from affected children worldwide. However, because enterovirus D68 has rarely been isolated directly from the spinal cord tissue, the causal link remained debated for years.25PubMed Central. Enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality The condition is not caused by poliovirus and does not indicate a polio resurgence, but the clinical similarity is close enough to generate confusion among parents and in news coverage.
Post-Polio Syndrome
Even people who survived paralytic polio decades ago are not necessarily done with the disease. Between a quarter and 40 percent of polio survivors eventually develop post-polio syndrome, a condition where new muscle weakness, fatigue, and sometimes pain emerge 15 to 40 years after the original illness.26PubMed Central. Post-Polio Syndrome Revisited The weakness tends to progress slowly and can affect muscles that seemed to have recovered fully, as well as muscles that were not obviously involved in the original bout of polio.27PubMed. Post-poliomyelitis syndrome
The syndrome can involve more than just limbs. Some patients develop new weakness in the muscles of the larynx, leading to difficulty swallowing, hoarseness, and breathing problems.28PubMed. New laryngeal muscle weakness in post-polio syndrome Post-polio syndrome is thought to result from the gradual wearing out of motor neurons that took on extra duty to compensate for neurons destroyed during the original infection. Those overworked neurons eventually start to fail, and the body has no more reserves to recruit. There is no cure, and treatment focuses on managing symptoms and conserving energy. The existence of post-polio syndrome means that even if all new polio transmission were stopped tomorrow, the disease would continue to affect millions of survivors for decades to come.